BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9873368)

  • 1. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
    Tabuchi S; Nakanishi I; Satoh Y
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
    Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
    J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
    Sinha J; Kurup A; Paleti A; Gupta SP
    Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
    J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
    Harper EA; Griffin EP; Shankley NP; Black JW
    Br J Pharmacol; 1999 Mar; 126(6):1496-503. PubMed ID: 10217545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
    J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
    Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
    J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands.
    Finizia G; Donati D; Pentassuglia G; Polinelli S; Tarzia G; Tranquillini ME; Ursini A
    Arch Pharm (Weinheim); 1998 Jan; 331(1):41-4. PubMed ID: 9507701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.
    Bellier B; Da Nascimento S; Meudal H; Gincel E; Roques BP; Garbay C
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1419-24. PubMed ID: 9871777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of brain penetration of CCK-B antagonists.
    Dubroeucq MC; Guyon C; Manfré F; Capet M; Barreau M; Bertrand P; Jeantaud B; Doble A; Blanchard JC
    Ann N Y Acad Sci; 1994 Mar; 713():377-9. PubMed ID: 8185193
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of dual histamine H2 and gastrin receptor antagonists with noncyclic gastrin receptor antagonistic moieties.
    Kawanishi Y; Ishihara S; Kiyama R; Hagishita S; Tsushima T; Ishikawa M; Ishihara Y
    Bioorg Med Chem; 1997 Jul; 5(7):1425-31. PubMed ID: 9377102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P; Delarge J; Pirotte B
    Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
    J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.